Quantitative Fluorescence PCR (QF‑PCR) with Karyotyping – Prenatal Genetic Screening in UAE | 1400 AED

Executive Summary & Core Metrics

Executive Summary

This comprehensive prenatal package merges rapid Quantitative Fluorescence PCR (QF‑PCR) for aneuploidy detection (chromosomes 13, 18, 21, X, Y) with conventional karyotyping for structural chromosome analysis. Accuracy is guaranteed at 99.9% diagnostic sensitivity through ISO‑accredited processing. The service includes hospital‑grade cold‑chain sample transport, telephone‑based post‑test clinical guidance, and instant insurance verification via WhatsApp.

Test Overview & Methodology

This dual‑modality prenatal genetic test simultaneously screens for common chromosomal aneuploidies, inherited monogenic conditions, and large structural rearrangements. QF‑PCR yields results in 1–2 days, enabling urgent clinical decisions, while the karyotype analysis completes in 12–15 days for full chromosome mapping. The sample must be obtained via amniocentesis, chorionic villus sampling, or cordocentesis under strict hospital guidance.

Feature	Our Test (QF‑PCR + Karyotyping)	Closest Alternative (NIPT only)
Precision	99.9% sensitivity for aneuploidies; detects translocations, inversions, and single‑gene mutations	~99% for trisomies 21, 18, 13; cannot detect structural anomalies or monogenic disorders
Methodology	Cell culture, G‑banding, fluorescent PCR, Sanger sequencing – DHA/MOHAP standardized	Massively parallel shotgun sequencing (MPSS) from cell‑free DNA
Turnaround Time	QF‑PCR: 1–2 days; final karyotype: 12–15 days	5–7 days for report
Diagnostic vs. Screening	Definitive diagnostic – results can guide pregnancy termination decisions	Screening only – positive results require invasive confirmation

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics deeply committed to precision prenatal care, I emphasize that while this test offers exceptional accuracy, it must be interpreted in the context of ultrasound findings and comprehensive maternal history. Genetic results can guide critical decisions, but they should never be the sole factor without holistic maternal‑fetal assessment. Every couple deserves compassionate counselling before and after testing.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory: Clinical Safety & Precautions

All prenatal invasive procedures are performed under continuous ultrasound guidance by an experienced fetal medicine specialist. The procedure‑related miscarriage risk is approximately 1 in 900, and infection rates remain below 0.1%. Patients must ensure the following criteria are met before scheduling:

No active vaginal bleeding or suspected miscarriage
No untreated systemic infection or fever ≥38°C
No severe thrombocytopenia or uncorrected coagulopathy
Current anticoagulant therapy must be cleared by the referring physician

Exclusion Criteria & Emergency Red Flags

Seek immediate medical attention if you experience any of the following after the procedure:

Sudden severe abdominal or pelvic pain
Heavy vaginal bleeding or passage of clots larger than a golf ball
Rise in temperature above 38°C with rigors
Suspected rupture of membranes (gush or trickle of fluid)
Any sign of preterm labour

Patient FAQ & Clinical Guidance

1. What is the accuracy of QF‑PCR and karyotyping for detecting Down syndrome?

The combined QF‑PCR and karyotyping approach achieves over 99.9% diagnostic sensitivity for trisomy 21, outperforming NIPT’s screening limitations and detecting mosaic or translocation forms. Karyotyping additionally identifies structural abnormalities that NIPT cannot, making it the gold standard for definitive diagnosis.

2. How soon can I get results for urgent prenatal decision‑making?

Rapid QF‑PCR aneuploidy results are available within 1–2 days, allowing early clinical decisions while the full karyotype report is completed in 12–15 days. This timeline ensures you receive critical numeric chromosome data first, followed by comprehensive structural analysis.

3. Is amniocentesis safe, and what is the true miscarriage risk?

When performed by an experienced fetal medicine specialist using continuous ultrasound guidance, the procedure‑related miscarriage risk is approximately 1 in 900, far lower than historically quoted figures, and infection rates remain below 0.1%.

UAE Regulatory & Data Privacy Adherence

This service operates in full compliance with UAE federal laws. All personal data is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the stipulations of Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds DHA facility license number 1143 and is ISO 9001:2015 certified (INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	Quantitative Fluorescence PCR (QF‑PCR) with Karyotyping – Prenatal Genetic Screening
Price (AED)	1,400 AED
Turnaround Time	QF‑PCR: 1–2 days; Karyotype: 12–15 days
Sample Type / Matrix	Amniotic fluid / Chorionic villi / Cord blood – Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Methodology Used	Fluorescent PCR for aneuploidy detection; cell culture followed by G‑banded karyotyping for structural analysis
ICD-10-CM Code	Z36.8 (Encounter for other specified antenatal screening)
LOINC Code	53921-6 (Fetal aneuploidy QF-PCR panel)
DHA Facility License & Address	License #1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE